|
|
|
|
|
Legal status
Patent lapsed (non-payment of fees)
| (51) | INT.CL. | A61K 35/28 | (2015.01) |
| A61K 38/00 | (2006.01) | ||
| A61P 7/00 | (2006.01) | ||
| A61P 7/06 | (2006.01) | ||
| C12N 9/22 | (2006.01) | ||
| C12N 15/90 | (2006.01) |
| (11) | Number of the document | 3504229 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17844404.8 |
| Date of filing the European patent application | 2017-08-24 | |
| (97) | Date of publication of the European application | 2019-07-03 |
| (45) | Date of publication and mention of the grant of the patent | 2021-10-13 |
| (46) | Date of publication of the claims translation | 2021-12-10 |
| (86) | Number | PCT/US2017/048397 |
| Date | 2017-08-24 |
| (87) | Number | WO 2018/039440 |
| Date | 2018-03-01 |
| (30) | Number | Date | Country code |
| 201662378978 P | 2016-08-24 | US | |
| 201762443981 P | 2017-01-09 | US | |
| 201762545778 P | 2017-08-15 | US |
| (72) |
MILLER, Jeffrey C. , US
REBAR, Edward J. , US
|
| (73) |
Sangamo Therapeutics, Inc. ,
7000 Marina Blvd, Brisbane, CA 94005,
US
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Genų raiškos reguliavimas, panaudojant rekombinantines nukleazes |
| REGULATION OF GENE EXPRESSION USING ENGINEERED NUCLEASES |
| Payment date | Validity (years) | Amount | |
| 2023-08-01 | 7 | 162.00 EUR |
| Patent lapsed (non-payment of fees) | ||
| Invalidation date | 2024-08-24 |